Contact: Jennifer Cook Williams
Investor Relations
360-668-3701

CLINICAL DATA FROM TRIAL OF IMMUNOCELLULAR THERAPEUTICS' CANCER VACCINE ICT-107 TO BE PRESENTED AT ASCO 2009 ANNUAL MEETING

LOS ANGELES, CA – May 26, 2009 – ImmunoCellular Therapeutics, Ltd. (OTC: IMUC.OB) (IMUC), a biotechnology company, today announced that clinical data from the company's Phase 1 trial of cancer vaccine ICT-107, will be presented at the American Society of Clinical Oncology (ASCO) 2009 Annual Meeting taking place May 29 through June 2, 2009 in Orlando, Florida.

Following are the presentation details:

Abstract #2032: "A phase I trial of tumor associated antigen-pulsed dendritic cell immunotherapy for patients with brain stem glioma and glioblastoma." Poster to be presented in the Central Nervous System Tumors session on May 31, 2009, 8:00 a.m. to 12:00 p.m. EDT (Level 2, West Hall C) by Surasak Phuphanich, MD, FAAN, principal investigator on the trial and neurosurgeon at Cedars-Sinai Medical Center.

About ICT-107

ICT-107 is IMUC's patient-specific therapeutic cancer vaccine that consists of dendritic cells—immune system cells responsible for presenting antigens (immune system targets) to the immune system—which are obtained from the patient's blood and "programmed" with tumor antigens, which in turn provide a target for the immune system. The immune system should then be armed to seek and destroy any remaining glioblastoma cells. While encouraging data has been observed from ICT-107, IMUC's primary focus is on its lead product candidate, ICT-121, which is an "off-the-shelf" cancer vaccine that targets cancer stem cells and may have applicability to multiple types of cancer. IMUC anticipates filing an Investigational New Drug (IND) application in the third quarter of 2009 for a Phase 1 trial of ICT-121 in the treatment of glioblastoma (brain cancer).

About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune based therapies for the treatment of brain and other cancers. The company's "off the shelf" therapeutic vaccine product candidate targeting cancer stem cells for multiple cancer indications is expected to enter clinical trials during the fourth quarter of 2009. IMUC has recently completed a Phase 1 trial of its dendritic cell-based clinical product candidate for glioblastoma. IMUC is in pre-clinical development of a monoclonal antibody product candidate for the treatment of small cell lung cancer and pancreatic cancer, and is also evaluating its platform technology for monoclonal antibody discovery using differential immunization for diagnosing and treating multiple types of cancer. To learn more about IMUC, please visit www.imuc.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including without limitation the risks associated with obtaining FDA clearance to commence clinical trials of the cancer stem cell vaccine on a timely basis or at all; the risks associated with adhering to projected preclinical or clinical timelines and the uncertainties of outcomes of development work for product candidates, including those based on destroying cancer stem cells as a potentially safe and effective treatment for various cancers; the need to satisfy performance milestones to maintain the vaccine technology licenses with Cedars-Sinai; the risk of obtaining patent coverage for the cancer stem cell vaccine; and the need for substantial additional capital to fund development of product candidates beyond their initial clinical or pre-clinical stages. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

###